UA100852C2 - Композиции для лечения рака - Google Patents

Композиции для лечения рака

Info

Publication number
UA100852C2
UA100852C2 UAA200908564A UAA200908564A UA100852C2 UA 100852 C2 UA100852 C2 UA 100852C2 UA A200908564 A UAA200908564 A UA A200908564A UA A200908564 A UAA200908564 A UA A200908564A UA 100852 C2 UA100852 C2 UA 100852C2
Authority
UA
Ukraine
Prior art keywords
treating cancer
composition
provides
mailer
kits
Prior art date
Application number
UAA200908564A
Other languages
English (en)
Ukrainian (uk)
Inventor
Валерия ОССОВСКАЯ
Линьюнь Ли
Барри Шерман
Пауэлл Кети
Нава Стефен
Н. Хан Хелен
Дж. Бастин Ричард
Original Assignee
Байпар Сайенсиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39350967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA100852(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Байпар Сайенсиз, Инк. filed Critical Байпар Сайенсиз, Инк.
Publication of UA100852C2 publication Critical patent/UA100852C2/ru

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Medical Informatics (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Изобретение касается фармацевтической композиции в форме водного раствора для инъекций, который содержит 4-йод-3-нитробензамид, применения композиции для лечения рака и вирусных заболеваний и способа лечения рака и вирусных заболеваний.
UAA200908564A 2007-01-16 2008-01-16 Композиции для лечения рака UA100852C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88075507P 2007-01-16 2007-01-16
PCT/US2008/051214 WO2008089272A1 (en) 2007-01-16 2008-01-16 Formulations for cancer treatment

Publications (1)

Publication Number Publication Date
UA100852C2 true UA100852C2 (ru) 2013-02-11

Family

ID=39350967

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200908564A UA100852C2 (ru) 2007-01-16 2008-01-16 Композиции для лечения рака

Country Status (33)

Country Link
US (1) US20080176946A1 (ru)
EP (2) EP2476461A3 (ru)
JP (1) JP2010516626A (ru)
KR (1) KR20090113852A (ru)
CN (1) CN101668561A (ru)
AU (1) AU2008206294A1 (ru)
BR (1) BRPI0806590A2 (ru)
CA (1) CA2674600A1 (ru)
CO (1) CO6220840A2 (ru)
CR (1) CR10975A (ru)
CY (1) CY1113819T1 (ru)
DK (1) DK2121139T3 (ru)
DO (1) DOP2009000178A (ru)
EC (1) ECSP099577A (ru)
ES (1) ES2395690T3 (ru)
GB (1) GB2447796C (ru)
GT (1) GT200900201A (ru)
HK (2) HK1121697A1 (ru)
HR (1) HRP20120960T1 (ru)
IL (1) IL199682A0 (ru)
MA (1) MA34559B1 (ru)
MX (1) MX2009007596A (ru)
NZ (1) NZ579098A (ru)
PL (1) PL2121139T3 (ru)
PT (1) PT2121139E (ru)
RS (1) RS52633B (ru)
RU (2) RU2481830C2 (ru)
SG (1) SG178714A1 (ru)
SI (1) SI2121139T1 (ru)
SV (1) SV2009003335A (ru)
TN (1) TN2009000292A1 (ru)
UA (1) UA100852C2 (ru)
WO (1) WO2008089272A1 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7961081B2 (en) * 2003-05-22 2011-06-14 John Tomlienovic Anti-theft system and method
KR20080031266A (ko) * 2005-06-10 2008-04-08 바이파 사이언스 인코포레이티드 Ｐａｒｐ 조절제 및 암의 치료
SG164368A1 (en) 2005-07-18 2010-09-29 Bipar Sciences Inc Treatment of cancer
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
CA2655257A1 (en) * 2006-06-12 2008-12-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
WO2008030892A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
CA2662517A1 (en) 2006-09-05 2008-03-13 Jerome Moore Treatment of cancer
WO2008030891A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
JP2011500684A (ja) * 2007-10-19 2011-01-06 バイパー サイエンシズ，インコーポレイティド ベンゾピロン系ｐａｒｐ阻害剤を用いる癌の処置方法および組成物
US7732491B2 (en) 2007-11-12 2010-06-08 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
CN101999002A (zh) * 2008-02-04 2011-03-30 彼帕科学公司 诊断和治疗parp-介导的疾病的方法
US8026271B2 (en) * 2008-07-11 2011-09-27 National Health Research Institutes Formulations of indol-3-yl-2-oxoacetamide compounds
WO2010036226A1 (en) * 2008-09-26 2010-04-01 George Nelson Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis
US20110020392A1 (en) * 2008-10-14 2011-01-27 Salubrious Pharmaceutical, Llc Process for treatment of rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis and non-viral based cancers
WO2012151701A1 (en) * 2011-05-10 2012-11-15 Université Laval / Vice-Rectorat À La Recherche Et À La Création Methods for the treatment and diagnostic of pulmonary arterial hypertension
CN107970214A (zh) * 2012-11-30 2018-05-01 葛兰素史克公司 新型药物组合物
US10610590B2 (en) 2016-05-02 2020-04-07 Symbios Technologies, Inc. Electrochemical plasma activated aqueous chemotherapeutics
EP3655418A4 (en) 2017-06-22 2021-05-19 Triact Therapeutics, Inc. METHOD OF TREATMENT OF GLIOBLASTOMA
AU2018341479B2 (en) 2017-09-26 2022-02-17 Tesaro, Inc. Niraparib formulations
EP3687501A4 (en) * 2017-09-29 2021-06-23 Triact Therapeutics, Inc. INIPARIB FORMS AND USES THEREOF
US20220218660A1 (en) * 2019-06-04 2022-07-14 Samsung Life Public Welfare Foundation Composition for treating castration-resistant prostate cancer, comprising quassinoids
CZ309587B6 (cs) * 2021-01-22 2023-05-03 Oncora S.R.O. Mikroemulzní prekoncentrát s obsahem kladribinu a způsob jeho přípravy
GB2611315B (en) * 2021-09-29 2024-01-03 Siemens Healthcare Gmbh Method of operating a magnetic resonance scanner
WO2023239919A1 (en) * 2022-06-10 2023-12-14 Dana-Farber Cancer Institute, Inc. Allelic imbalance of chromatin accessibility in cancer identifies causal risk variants and their mechanisms

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0348655A (ja) * 1989-07-14 1991-03-01 Shionogi & Co Ltd プロスタグランジンｄ↓２類の安定化
US5633282A (en) * 1990-05-25 1997-05-27 British Technology Group Limited Inhibition of viral infection
US5232735A (en) * 1990-06-01 1993-08-03 Bioresearch, Inc. Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers
US5637618A (en) * 1990-06-01 1997-06-10 Bioresearch, Inc. Specific eatable taste modifiers
US5631038A (en) * 1990-06-01 1997-05-20 Bioresearch, Inc. Specific eatable taste modifiers
US5484951A (en) * 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
US5877185A (en) * 1991-10-22 1999-03-02 Octamer, Inc. Synergistic compositions useful as anti-tumor agents
US5464871A (en) * 1993-05-12 1995-11-07 Octamer, Inc. Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
US5753674A (en) * 1991-10-22 1998-05-19 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents, anti-retroviral agents and anti-tumor agents
US5516941A (en) * 1991-10-22 1996-05-14 Octamer, Inc. Specific inactivators of "retroviral" (asymmetric) zinc fingers
US5482975A (en) * 1991-10-22 1996-01-09 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents
GB9200247D0 (en) * 1992-01-07 1992-02-26 Erba Carlo Spa Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation
US5558855A (en) 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
US6008250A (en) * 1993-05-26 1999-12-28 Bioresearch, Inc. Specific eatable taste modifiers
US6015792A (en) * 1993-05-26 2000-01-18 Bioresearch, Inc. Specific eatable taste modifiers
US5589483A (en) * 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
AU5780696A (en) * 1995-06-02 1996-12-18 Takeda Chemical Industries Ltd. Stabilized composition comprising an antiulcerative benzimid azole
US5837729A (en) * 1996-04-26 1998-11-17 Metatron, Inc. Methods for treating and preventing HIV infection using acetaminophen and derivatives thereof
AU7074298A (en) * 1997-04-10 1998-10-30 Foster, Robert T. Activated iododerivatives for the treatment of cancer and aids
US5908861A (en) * 1997-05-13 1999-06-01 Octamer, Inc. Methods for treating inflammation and inflammatory disease using pADPRT inhibitors
US6696426B2 (en) * 2000-08-22 2004-02-24 Pharmacia Corporation Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems
BR0116658A (pt) * 2001-01-04 2003-12-30 Daiichi Seiyaku Co Preparação farmacêutica contendo ciclodextrina
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
JP2003321364A (ja) * 2002-05-07 2003-11-11 Eisai Co Ltd シクロデキストリンにより可溶化及び安定化された抗腫瘍剤含有組成物
MXPA05007552A (es) * 2003-01-14 2006-05-19 Teva Pharma Formulaciones parenterales de un peptido para el tratamiento de lupus sistemico eritematoso.
WO2005023765A1 (en) * 2003-09-11 2005-03-17 Pharmacia & Upjohn Company Llc Method for catalyzing amidation reactions by the presence of co2
KR20080031266A (ko) * 2005-06-10 2008-04-08 바이파 사이언스 인코포레이티드 Ｐａｒｐ 조절제 및 암의 치료
SG164368A1 (en) * 2005-07-18 2010-09-29 Bipar Sciences Inc Treatment of cancer
CA2655257A1 (en) * 2006-06-12 2008-12-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
CA2662517A1 (en) * 2006-09-05 2008-03-13 Jerome Moore Treatment of cancer
US20080076778A1 (en) * 2006-09-05 2008-03-27 Bipar Sciences, Inc. Methods for designing parp inhibitors and uses thereof
WO2008030891A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
WO2008030892A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof

Also Published As

Publication number Publication date
KR20090113852A (ko) 2009-11-02
CN101668561A (zh) 2010-03-10
HK1121697A1 (en) 2009-04-30
GB2447796A (en) 2008-09-24
RU2012151571A (ru) 2014-06-10
PL2121139T3 (pl) 2013-03-29
ECSP099577A (es) 2009-10-30
SV2009003335A (es) 2010-02-05
GB2447796C (en) 2009-11-12
TN2009000292A1 (en) 2010-12-31
IL199682A0 (en) 2010-04-15
PT2121139E (pt) 2012-12-12
BRPI0806590A2 (pt) 2013-07-23
AU2008206294A1 (en) 2008-07-24
MA34559B1 (fr) 2013-10-02
GB0807263D0 (en) 2008-05-28
CR10975A (es) 2009-10-15
HK1137158A1 (en) 2010-07-23
CA2674600A1 (en) 2008-07-24
US20080176946A1 (en) 2008-07-24
EP2476461A3 (en) 2012-10-24
RS52633B (en) 2013-06-28
RU2481830C2 (ru) 2013-05-20
HRP20120960T1 (hr) 2012-12-31
CY1113819T1 (el) 2016-07-27
CO6220840A2 (es) 2010-11-19
SI2121139T1 (sl) 2013-01-31
DOP2009000178A (es) 2009-10-31
EP2121139A1 (en) 2009-11-25
NZ579098A (en) 2012-07-27
WO2008089272A1 (en) 2008-07-24
EP2121139B1 (en) 2012-10-10
EP2476461A2 (en) 2012-07-18
SG178714A1 (en) 2012-03-29
ES2395690T3 (es) 2013-02-14
GB2447796B (en) 2009-03-04
GT200900201A (es) 2011-06-23
RU2009130599A (ru) 2011-02-27
DK2121139T3 (da) 2013-01-14
JP2010516626A (ja) 2010-05-20
MX2009007596A (es) 2009-08-13

Similar Documents

Publication Publication Date Title
UA100852C2 (ru) Композиции для лечения рака
SG164368A1 (en) Treatment of cancer
MX2009009948A (es) Derivados de piridazinona utiles como inhibidores de glucano sintasa.
MX2011010390A (es) Conjugados, particulas, composiciones de agentes polimericos y metodos relacionados de uso.
UA100840C2 (ru) Композиция для лечения вирусного гепатита
UA95310C2 (ru) Композиция, содержащая ингибитор chk1 и циклодекстрин, для лечения рака
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
PT2155188E (pt) Métodos e composições para o tratamento de cancro recorrente
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
WO2008030883A3 (en) Treatment of cancer
PL1951729T3 (pl) Pochodne pirymidyny połączone przez atom tlenu
WO2006107451A3 (en) Honokiol derivatives for the treatment of proliferative disorders
MX2012000396A (es) Metodos y composiciones para uso en tartamientos celulares.
TW200604192A (en) Compounds and methods for inhibiting mitotic progression
UA98804C2 (ru) Катехоламиновые производные и фармацевтическая композиция на их основе
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
UA91848C2 (ru) Применение соединений диосметина в лечении и предотвращении тромботическим патологиям
MX2010003365A (es) Derivados de tiazol para el tratamiento de cancer.
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
MXPA05008902A (es) Soluciones de drogas en mentol.
DE602005015329D1 (de) Rutheniumkomplexe zur krebsbehandlung
RU2011134979A (ru) Композиция для снижения жесткости воды
EP2124554A4 (en) COMPOSITIONS AND METHODS FOR CANCER TREATMENT
TN2010000232A1 (en) Formulations for cancer treatment